Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Genetic Screens02:46

Genetic Screens

5.8K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Cancer02:18

Cancer

54.6K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.6K
What is Cancer?02:12

What is Cancer?

14.5K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.5K
Cancer Prevention02:59

Cancer Prevention

8.2K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.2K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between baseline prostate MRI PI-RADS classification and risk of Gleason upgrade during active surveillance: a systematic review and meta-analysis.

World journal of urology·2026
Same author

Performance of the Prostate Health Index Test in Men With Prostate Specific Antigen Levels Between 10 and 20 ng/mL.

Urology·2025
Same author

The Long Road to Healthcare Quality Standardization and Optimization in Urology.

Urology·2025
Same author

Letter: The Impact of American Board of Urology Certification on Postoperative Outcomes for Patients in New York State.

Urology practice·2025
Same author

Risks of grade reclassification among patients with Gleason grade group 1 prostate cancer and PI-RADS 5 findings on prostate MRI.

Urologic oncology·2024
Same author

Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active Surveillance.

JAMA oncology·2024
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.7K

Prostate Cancer Screening.

William J Catalona1

  • 1Department of Urology, Northwestern University Feinberg School of Medicine, 675 North Saint Clair Street, Suite 20-150, Chicago, IL 63110, USA.

The Medical Clinics of North America
|February 7, 2018
PubMed
Summary
This summary is machine-generated.

Prostate cancer (PCa) screening significantly reduces mortality. Recent shifts in recommendations highlight shared decision-making for men aged 55-69, emphasizing personalized screening strategies.

Keywords:
History of prostate cancer screeningPSAProstateProstate cancerProstate cancer screeningProstate cancer screening guidelinesProstate-specific antigenUnited States Preventive services Task Force

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.5K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K

Related Experiment Videos

Last Updated: Feb 14, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

14.7K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

8.5K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.9K

Area of Science:

  • Oncology
  • Public Health
  • Preventive Medicine

Background:

  • Prostate-specific antigen (PSA) screening has historically reduced prostate cancer (PCa) mortality by 53% in the US.
  • Concerns regarding overdiagnosis and overtreatment led to a recommendation against PCa screening, causing a rise in advanced diagnoses.
  • Evolving data and active surveillance acceptance prompted revised screening guidelines.

Purpose of the Study:

  • To analyze the impact of PSA screening on prostate cancer mortality.
  • To evaluate the shift in screening recommendations and its consequences.
  • To inform current and future prostate cancer screening strategies.

Main Methods:

  • Review of historical prostate cancer screening data and mortality rates.
  • Analysis of clinical trial data and guideline evolution.
  • Assessment of the impact of screening changes on disease presentation.

Main Results:

  • A 53% decrease in US PCa mortality was observed during the PSA screening era.
  • A decline in screening led to a resurgence of high-risk prostate cancer diagnoses.
  • Revised guidelines now advocate for shared decision-making for specific age groups.

Conclusions:

  • Prostate cancer screening remains a critical tool for reducing morbidity and mortality.
  • Personalized screening approaches, including shared decision-making, are essential.
  • Further research is needed for intensive screening in high-risk populations.